表没食子儿茶素没食子酸酯相关肿瘤临床试验研究进展

作者：Lei Mengxia; Wang Dandan; Yu Fei; Jin Xiaoying; Chen Xuesong^*

来源：Chinese Journal of Clinical Oncology, 2018, 45(2): 97-102.

DOI：10.3969/j.issn.1000-8179.2018.02.523

• Clinical trial
• Epigallo-catechingallate (EGCG)
• Safety
• Tumor

Epigallo-catechingallate (EGCG), the most abundant polyphenol and important active ingredient in green tea, is widely studied in cancer prevention and treatment. It has demonstrated various anti-cancer activities in vitro and in vivo, including induction of apoptosis, as well as inhibition of tumor cell invasion, migration, and angiogenesis. EGCG has been in the clinical stage of drug development with some findings currently available. In the present review, we systematically summarize the research advances of EGCG in cancer treatment through collection of global clinical trials and related results and discuss its safety, research efficacy, and critical challenges. ? 2018 China Anti-Cancer Association. All Rights Reserved.